Mycophenolate mofetil

Organ Transplant Rejection Prevention

Mycophenolate mofetil is primarily used to prevent the body from rejecting a transplanted organ. When a person receives an organ from a donor, their immune system may recognize the new organ as foreign and attempt to attack it. This medication helps suppress that immune response in patients receiving the following types of transplants:

• Kidney transplants
• Heart transplants
• Liver transplants

Combination Therapy

This medication is rarely used alone for transplant patients. It is usually prescribed as part of a multi-drug treatment regimen to provide the best protection for the new organ. It is commonly used alongside other immunosuppressive drugs, such as:

• Corticosteroids (such as prednisone)
• Cyclosporine

By using a combination of medications that work in different ways, healthcare providers can more effectively manage the immune system's activity and reduce the risk of the body rejecting the donor organ.

Preventing Organ Rejection

The immune system is the body's natural defense against foreign invaders, such as bacteria and viruses. When a person receives a transplanted organ, like a kidney, heart, or liver, the immune system may identify the new organ as foreign and try to attack it. This reaction is called organ rejection.

Targeting Immune Cells

Mycophenolate mofetil works by suppressing the activity of the immune system. Specifically, it interferes with the body's ability to produce certain types of white blood cells called lymphocytes. These cells are primarily responsible for recognizing and attacking foreign tissue.

By limiting the production and growth of these cells, the medication helps the body accept the new organ. This process involves:

• Reducing the immune system's response to the transplanted tissue.
• Lowering the risk of the body attacking the new organ.
• Helping the transplanted organ continue to function as intended.

Common Side Effects

Many people taking mycophenolate mofetil experience mild to moderate side effects. These often include:

• Stomach issues such as nausea, vomiting, diarrhea, constipation, or stomach pain
• Headache or dizziness
• Difficulty falling asleep or staying asleep
• Tremors or shaking in a part of the body
• Swelling of the hands, ankles, or feet
• Back, muscle, or joint pain
• Gas or loss of appetite

Serious Side Effects

Some side effects can be serious and require immediate medical attention. Contact a healthcare provider right away if you experience:

• Signs of infection, such as fever, chills, sore throat, or cough
• Unusual bleeding or bruising
• Black, tarry, or bloody stools
• Vomiting blood or material that looks like coffee grounds
• Chest pain or a fast, pounding, or irregular heartbeat
• Shortness of breath
• Yellowing of the skin or eyes
• Pain or burning during urination
• New skin growths or changes in the size or color of a mole
• Extreme tiredness or pale skin

Serious Risks and Boxed Warnings

Mycophenolate mofetil has several boxed warnings due to the potential for severe side effects:

• Pregnancy Risks: Use during pregnancy is associated with an increased risk of first-trimester pregnancy loss (miscarriage) and birth defects. Females of reproductive potential must follow specific contraception requirements and participate in a safety program called a Risk Evaluation and Mitigation Strategy (REMS).
• Infections: This medication suppresses the immune system, which increases the risk of developing serious bacterial, viral, fungal, and protozoal infections. These infections can lead to hospitalization or death.
• Malignancy: There is an increased risk of developing lymphomas and other cancers, particularly skin cancer. It is recommended to limit exposure to sunlight and ultraviolet (UV) light by wearing protective clothing and using sunscreen.

Other Important Precautions

Healthcare providers monitor for several other serious conditions during treatment:

• Brain Infection: Progressive multifocal leukoencephalopathy (PML), a rare and potentially fatal brain infection, has been reported. Symptoms may include clumsiness, changes in vision, or memory loss.
• Stomach and Intestinal Issues: There is a risk of serious gastrointestinal problems, including bleeding, ulcers, and perforations.
• Blood Disorders: The medication can cause low white blood cell counts (neutropenia) or a condition called pure red cell aplasia (PRCA), where the body stops making red blood cells. Regular blood tests are required to monitor for these issues.
• Vaccinations: Live vaccines should be avoided during treatment because the medication may make the vaccine less effective or increase the risk of infection from the vaccine.

Individuals with certain rare inherited enzyme deficiencies, such as Lesch-Nyhan or Kelley-Seegmiller syndromes, should generally avoid using this medication.

Pregnancy Risks

Mycophenolate mofetil can cause serious harm to an unborn baby. Taking this medication during pregnancy significantly increases the risk of miscarriage, particularly during the first trimester. It also carries a high risk of birth defects, which may affect the development of the ears, face, heart, and other organs.

Prevention and Planning

Because of these risks, healthcare providers require specific precautions for individuals who can become pregnant:

• Pregnancy tests are typically required before starting treatment and at regular intervals during therapy.
• Effective birth control must be used before starting the medication, throughout the entire treatment period, and for at least six weeks after the last dose.
• Patients are often required to participate in a restricted distribution program (REMS) to ensure they understand the risks and follow safety protocols.

Men taking mycophenolate mofetil should also use effective contraception, such as condoms, during treatment and for at least 90 days after their final dose to prevent pregnancy in their partners.

Breastfeeding

It is not currently known if mycophenolate mofetil passes into human breast milk. Due to the potential for serious side effects in a nursing child, experts generally advise against breastfeeding while using this medication. Patients should discuss feeding options and potential risks with their healthcare provider before starting treatment.

Oral Formulations

Mycophenolate mofetil is commonly administered by mouth in the following forms:

• Capsules
• Tablets
• Oral suspension (a liquid form)

Injectable Formulations

For patients who cannot take medication by mouth, mycophenolate mofetil is available as a:

• Powder for injection (reconstituted and administered as an intravenous infusion by a healthcare professional)

FDA Approval and Indications

Mycophenolate mofetil is approved by the U.S. Food and Drug Administration (FDA) to prevent organ rejection in patients receiving kidney, heart, or liver transplants. It is typically used in combination with other medications, such as corticosteroids and cyclosporine.

Boxed Warning

The FDA requires a boxed warning for mycophenolate mofetil due to several significant safety concerns:

• Pregnancy Risks: Use during pregnancy is associated with an increased risk of first-trimester pregnancy loss (miscarriage) and serious congenital malformations (birth defects).
• Serious Infections: Patients are at an increased risk of developing serious bacterial, viral, fungal, and protozoal infections, including opportunistic infections that may be fatal.
• Malignancies: There is an increased risk of developing lymphomas and other malignancies, particularly of the skin.

Risk Evaluation and Mitigation Strategy (REMS)

Because of the risks of birth defects and miscarriage, the FDA has implemented a single shared Risk Evaluation and Mitigation Strategy (REMS) for all mycophenolate products. The Mycophenolate REMS program is designed to ensure that healthcare providers and patients are fully informed about these risks. It requires providers to counsel patients on the need for effective contraception and regular pregnancy testing before and during treatment.

Pregnancy Risks

Mycophenolate mofetil can cause serious harm to an unborn baby. There is a high risk of miscarriage (pregnancy loss), particularly during the first trimester. Additionally, infants exposed to this medication in the womb have a significant risk of being born with structural birth defects.

Common Birth Defects

• External ear abnormalities
• Cleft lip and cleft palate
• Heart defects
• Abnormalities of the limbs, kidneys, or esophagus

Safety Program and Testing

Because of these risks, the medication is only available through a restricted program called the Mycophenolate Risk Evaluation and Mitigation Strategy (REMS). Before starting treatment, women who can become pregnant must have a negative pregnancy test. Regular pregnancy testing is also required during treatment.

Contraception Requirements

Women of childbearing potential must use acceptable forms of birth control beginning four weeks before starting the medication, throughout the entire treatment period, and for at least six weeks after the final dose. Men with female partners who can become pregnant should use condoms during treatment and for at least 90 days after stopping the medication.

Breastfeeding

It is not known if mycophenolate mofetil passes into human breast milk. Due to the potential for serious side effects in a nursing infant, breastfeeding is generally not recommended while using this medication.